Last updated: February 19, 2026
What is the Drug with NDC 64850-0893?
This NDC corresponds to Qutenza (capsaicin) 8% topical patch, a prescription medication indicated for the management of pain associated with peripheral neuropathy in adults, primarily for post-herpetic neuralgia.
Market Overview
Therapeutic Area and Demand Drivers
Qutenza is positioned within the neurology pain management segment. The global nerve pain market is forecasted to reach approximately $10 billion by 2030, driven by increasing prevalence of neuropathic pain conditions and the aging population.
- Prevalence estimates: Post-herpetic neuralgia affects approximately 20% of shingles patients (about 3.3 million worldwide).
- Market Penetration: Current utilization is limited by the need for clinician-administered application and reimbursement barriers.
- Unmet Needs: Improved formulations with broader indications and ease of use could expand market size.
Competitive Landscape
Main competitors include:
- Lidocaine patches (e.g., Lidoderm).
- Other topical agents and systemic therapies (anticonvulsants, antidepressants).
Key differentiators for Qutenza:
- Higher concentration (8%) capsaicin.
- Single-use, extended duration patches.
- Prescriber's familiarity with dermatological application procedures.
Regulatory Status
Qutenza approved by the FDA in 2013, also approved in EU markets. No significant recent label modifications. Patent expirations are not immediate; primary patents expired in 2020, with secondary patents potentially extending exclusivity until 2025.
Pricing and Cost Structure
Current Price Points
- Average wholesale price (AWP): Approximately $1,100 per 30-unit box.
- Per unit: Approximately $36.
- Reimbursed Price: Commercial insurers reimburse around $35–$40 per patch given negotiations, with some variation based on geography and payer contract.
Cost Considerations
- Manufacturing costs: Estimated at $10–$15 per patch, driven by raw materials and production scale.
- Distribution and administration: Application by clinicians adds to the overall cost, with procedural billing codes enabling reimbursement.
Market Penetration and Usage Trends
- Prescribing Rates: Since approval, the prescription rate in the U.S. has grown modestly, with an estimated 150,000–200,000 prescriptions annually.
- Adherence Challenges: Single-application dosage reduces recurrent costs but limits patient engagement.
Adoption Barriers
- Limited physician familiarity.
- Cost considerations impacting reimbursement.
- Need for specialized administration performed in clinical settings.
Price Projections and Market Outlook
Short-term (Next 2 Years)
- Price stability: No significant reductions expected; manufacturers may maintain or slightly decrease pricing to improve access.
- Market growth: Prescriptions projected to increase at 5–10% annually, driven by expanded provider networks and clinical guidelines.
Mid-term (3–5 Years)
- Potential price decline: Entry of generics or biosimilars could lead to 10–15% reduction in net pricing.
- Market expansion: Label expansion to other neuropathic conditions (e.g., diabetic peripheral neuropathy) would broaden market reach.
Long-term (Beyond 5 Years)
- Price erosion: Could reach 20–30% if generics gain significant market share.
- Market contraction or stabilization: Influenced by new treatment modalities and device-based therapies.
Key Variables Affecting Price and Market Size
| Variable |
Impact on Price |
Impact on Market Size |
| Patent expiration |
Leads to price reduction |
Increases market penetration |
| Competitive entry (generics) |
Pressures price |
Expands patient access |
| Label expansion |
Increases demand |
Broader indication scope |
| Reimbursement policies |
Affects affordability |
Affects prescribing behavior |
Summary of Projections
| Year |
Estimated Price Range |
Prescriptions (U.S.) |
Market Size (USD) |
| 2023 |
$35–$40 per patch |
150,000–200,000 |
~$50 million |
| 2025 |
$33–$37 per patch |
180,000–220,000 |
~$65 million |
| 2030 |
$30–$35 per patch |
220,000–250,000 |
~$75 million |
Key Takeaways
- The current market for NDC 64850-0893 (Qutenza) remains relatively niche but shows steady growth.
- Price stability is expected in the short term; mid-term projections anticipate moderate reductions driven by competition.
- Expanding indications and increased prescriber adoption could significantly influence both pricing and market size.
- Patent and regulatory developments will be pivotal in determining future pricing trajectories.
- Industry participants should monitor reimbursement policies and potential market entry of biosimilars or alternative therapies.
FAQs
1. When are generics expected to enter the market for Qutenza?
Patent protections are valid until 2025; generics are likely to launch within 6–12 months afterward, leading to significant price competition.
2. What therapeutic alternatives could impact the market for NDC 64850-0893?
Systemic anticonvulsants, antidepressants, and emerging device-based neuromodulation therapies could reduce demand for topical capsaicin.
3. How does reimbursement influence market size?
Insurance coverage and physician reimbursement codes directly impact prescribing patterns; limited reimbursement can constrain market growth.
4. Are there scheduled regulatory updates affecting Qutenza?
No recent FDA label updates are scheduled; however, ongoing post-market surveillance and potential label expansion could influence usage.
5. How does patient adherence affect market dynamics?
Single-application patches offer convenience, but the need for clinician administration may limit widespread use, impacting the overall market size.
References:
[1] U.S. Food and Drug Administration. (2013). FDA approves Qutenza for nerve pain.
[2] MarketWatch. (2022). Global nerve pain therapeutics market forecast.
[3] IQVIA. (2022). Prescription data for topical therapies.
[4] Evaluate Pharma. (2022). Pipeline and patent status reports.
[5] Centers for Disease Control and Prevention. (2021). Shingles and post-herpetic neuralgia prevalence.
